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Impact of 3rd generation drugs on the activity of first-line 
chemotherapy in advanced non-small cell lung cancer (NSCLC): a 
meta-analytical approach
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A two-drug platinum-based regimen with cisplatin or carboplatin 
combined with a third-generation agent gemcitabine (G), paclitaxel (P), 
vinorelbine (V), or docetaxel (D) is the standard ﬁrst-line treatment 
for advanced NSCLC patients. Large clinical trials comparing various 
third-generation doublets showed similar efﬁcacy.
The aim of this study is to assess the impact of G, P, V and D on the 
activity of ﬁrst-line chemotherapy in advanced NSCLC, we carried 
out four separate meta-analyses on data from 6,671 NSCLC patients 
who were enrolled in 18 randomized trials comparing a G or P or V or 
D-containing vs. G or P or V or D-free regimens. We constructed 2x2 
tables using response to treatment data. For trials with more than one 
eligible free comparator arm, individual comparisons between the G 
or P or V or D-based treatment arms and each of the comparator arms 
were analyzed. A general variance-based method was used to estimate 
the pooled odds ratio (OR) and 95% conﬁdence interval (CI). We as-
sessed for heterogeneity among the trials based on standard methods.
Seventeen, 9, 14 and 8 comparisons contributed to this analysis for G, 
P, V and D respectively. Comparing G-containing vs. G-free regimens, 
the OR for progression was 0.8633 (CI 95% 0.76-0.97; p=0.016); no 
signiﬁcant difference was observed for overall (complete + partial) 
response (OR 0.96, CI 95% 0.84-1.10). The heterogeneity chi-square 
were 12.97 (p=0.60) and 19.53 (p=0.24), respectively. Comparing 
P-containing vs. P-free regimens, no signiﬁcant difference was ob-
served for overall response (OR 0.96, CI 95% 0.83-1.11) while P was 
estimated to be associated to an increased risk of progression (OR 1.21, 
CI 95% 1.06-1.38; p=0.0045). The heterogeneity chi-square were 5.20 
(p=0.73) and 4.92 (p=0.76), respectively. Comparing V-containing vs. 
V-free regimens, no signiﬁcant difference was observed for both overall 
response (OR 0.98, CI 95% 0.83-1.15) and for progression (OR 1.06, 
CI 95% 0.92-1.21). The heterogeneity chi-square were 20.73 (p=0.07) 
and 9.03 (p=0.69), respectively. Comparing D-containing vs. D-free 
regimens, the OR for progression was 0.9313 (CI 95% 0.81-1.06; 
p=0.28); no signiﬁcant difference was observed for overall response 
(OR 0.95, CI 95% 0.77-1.17). The heterogeneity chi-square were 4.70 
(p=0.69) and 14.25 (p=0.04), respectively.
These data demonstrate a similar probability to obtain an overall re-
sponse between regimens. G containing regimens demonstrated a 14% 
reduction in the risk of an immediate progression. While P containing 
regimens were associated with a 21% increase in the risk of an im-
mediate progression. Further analyses are required to address whether 
disease control is associated with a survival beneﬁt and may therefore 
be used as a surrogate end point for survival in chemotherapy trials of 
NSCLC.
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A randomized Phase III study to compare the overall survival of 
gefitinib (IRESSA) versus docetaxel in Japanese patients with 
previously treated advanced non-small-cell lung cancer
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Background: This prospective randomized, open-label, Phase III study 
(V-15-32) compared overall survival between geﬁtinib (250 mg/day) 
and docetaxel (60 mg/m2) in pretreated patients with non-small-cell 
lung cancer (NSCLC).
Methods: Patients had advanced/metastatic NSCLC and had failed 
one/two chemotherapy regimens. Stratiﬁcation factors for random-
ization were sex (female vs. male), performance status (0-1 vs. 2), 
histology (adenocarcinoma vs. others) and study site. Non-inferiority of 
the primary endpoint, overall survival, was assessed by the conﬁdence 
interval (CI) of the geﬁtinib/docetaxel hazard ratio (HR) derived from 
an unadjusted Cox proportional hazards model. Secondary endpoints 
were progression free survival (PFS), time to treatment failure (TTF), 
objective response rate (ORR), disease control rate (DCR), quality of 
life (QoL; Functional Assessment of Cancer Therapy - Lung [FACT-
L]), disease-related symptoms (FACT-L lung cancer subscale [LCS]), 
and safety. Exploratory endpoints included biomarker expression in 
tumor tissue and potential correlation with outcome.
Results: Between September 2003 and January 2006, 489 eligible 
patients (62% male, 78% adenocarcinoma, 32% never-smokers) were 
recruited from 50 institutes. Treatment arms were generally well bal-
anced for baseline demographics. Non-inferiority in overall survival 
was not achieved (HR 1.12; 95.24% CI 0.89, 1.40) according to the 
predeﬁned criterion (upper CI limit for HR <1.25), however, no signiﬁ-
cant difference in overall survival was apparent between the treatment 
groups (p=0.330). Median survival times were 11.5 (geﬁtinib) and 
14.0 (docetaxel) months. Post-study, 36% of geﬁtinib-treated patients 
received subsequent docetaxel and 40% received no other therapy apart 
from geﬁtinib; 53% of docetaxel-treated patients received subsequent 
geﬁtinib and 26% received no other therapy apart from docetaxel. 
Geﬁtinib signiﬁcantly improved ORR (22.5% vs. 12.8%; p=0.009), 
TTF (HR 0.63; 95% CI 0.51, 0.77; p<0.001) and QoL improvement 
rates (FACT-L trial outcome index 20.5% vs. 8.7%; p=0.002; FACT-L 
23.4% vs. 13.9%; p=0.023), compared with docetaxel. No signiﬁcant 
differences between treatments were seen in PFS (HR 0.90; 95% 
CI 0.72, 1.12; p=0.335), DCR (34.0% vs. 33.2%; p=0.735) or LCS 
improvement rates (22.7% vs. 20.4%; p=0.562). Adverse events (AEs) 
were consistent with those previously seen with geﬁtinib and docetaxel. 
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Grade 3/4 AEs occurred in 40.6% (geﬁtinib) and 81.6% (docetaxel) 
of patients. The incidence of interstitial lung disease (ILD) was 5.7% 
(n=14) and 2.9% (n=7) with geﬁtinib and docetaxel, respectively. There 
were four deaths due to AEs in the geﬁtinib arm (three possibly treat-
ment-related due to ILD; one due to pneumonia that was not considered 
treatment-related), and none in the docetaxel arm. Biomarker data will 
also be reported.
Conclusions: Non-inferiority in overall survival between geﬁtinib 
and docetaxel was not demonstrated according to predeﬁned criteria. 
However, there was no statistically signiﬁcant difference in survival 
between the two groups. Imbalances in the proportion and type of 
post-study treatments in both arms have complicated interpretation of 
survival results. The secondary endpoints are largely unaffected by 
subsequent therapy and provide further evidence of the clinical efﬁcacy 
of geﬁtinib in Japanese patients. AEs were consistent with those previ-
ously observed for both treatments.
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Randomized, double-blind, multicenter, parallel-group, Phase II 
study of gefitinib (IRESSA) plus best supportive care (BSC) versus 
placebo plus BSC in chemotherapy-naïve patients with advanced 
non-small-cell lung cancer and poor performance status (INSTEP)
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Background: It is estimated that 30-40% of patients with advanced 
non-small-cell lung cancer (NSCLC) have a poor performance status 
(PS); however, there is no consensus on the best treatment approach 
for such patients (Gridelli et al, Ann Oncol 2004;15:419-426). In a 
large randomized four arm, Phase III study, the median survival for 
PS2 patients treated with combination chemotherapy was 3.9 months 
(Schiller et al, NEJM 2002;346:92-98). Single-agent chemotherapy is 
also an option for PS2 patients (Gridelli et al, Lung Cancer 2002;38:
S37-S41) but there is a need for effective treatment alternatives for pa-
tients considered unﬁt for chemotherapy or who refuse chemotherapy. 
A retrospective review of 198 chemotherapy-naïve patients (20% PS2 
and 3) with advanced NSCLC who received geﬁtinib (IRESSA) within 
a compassionate use program in the USA, reported a median survival 
of 6 months and objective response rate of 6.3% (Govindan et al. Lung 
Cancer 2006;53:331-337). The Phase II, randomized, double-blind, 
multicenter, parallel-group study reported here compared geﬁtinib plus 
BSC to placebo plus BSC in patients with advanced NSCLC and poor 
PS (IRESSA NSCLC Trial Evaluating Poor PS patients [INSTEP]).
Methods: This study planned to recruit approximately 200 patients. 
Following written, informed consent, patients (≥18 years) with locally 
advanced or metastatic (stage IIIB or IV) NSCLC who were chemo-
therapy-naïve, had a poor PS (WHO PS 2 or 3) and were considered 
unﬁt for chemotherapy were randomized to geﬁtinib (250 mg/day 
orally) plus BSC or placebo plus BSC. The primary objective of this 
study was to compare progression-free survival (PFS) between the 
two treatment groups. Secondary endpoints were objective response 
rate (assessed every 6 weeks using RECIST criteria), overall survival, 
patient-reported functionality and quality of life (via the Functional 
Assessment of Cancer Therapy-Lung [FACT-L] trial outcome index 
and total score, respectively), pulmonary symptom improvement (as 
measured by the pulmonary items of the FACT-L lung cancer sub-
scale), and tolerability (frequency and severity of adverse events [via 
CTC version 3.0] and laboratory parameters). An exploratory endpoint 
was to correlate the efﬁcacy of geﬁtinib with epidermal growth factor 
receptor (EGFR) gene copy number. A proportional hazards model 
(presenting a hazard ratio and its associated 95% conﬁdence intervals) 
will be used to compare PFS between treatment groups, with gender, 
PS, histology, smoking history, and stage as covariates. While median 
PFS on BSC is expected to be in the region of 4 weeks, there are no 
data upon which to accurately anticipate the effectiveness of geﬁtinib in 
this setting. With 200 patients recruited, this study would have greater 
than 90% power to detect a 75% improvement in PFS and 81% power 
to detect a 50% improvement in PFS.
Results: Between September 2004 and December 2006, 201 patients 
were randomized from 5 countries and 37 centers. Efﬁcacy, quality of 
life, safety and EGFR gene copy number results will be available for 
presentation at this meeting.
Conclusions: To be completed once data are available.
IRESSA is a trademark of the AstraZeneca group of companies
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A randomized multicenter phase III study of cetuximab 
(Erbitux®) in combination with Taxane/Carboplatin versus 
Taxane/Carboplatin alone as first-line treatment for patients with 
advanced/metastatic Non-small cell lung cancer (NSCLC)
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Background: Cetuximab (Erbitux®) is a chimeric monoclonal IgG1 
antibody targeting the epidermal growth factor receptor (EGFR) 
thereby blocking ligand-receptor interaction, promoting receptor 
internalization, cell cycle arrest and apoptosis. Several phase II studies 
with cetuximab in combination with platinum based chemotherapy 
have shown encouraging anti-tumor activity in patients with advanced/
metastatic NSCLC. This randomized phase III study was conducted to 
determine the efﬁcacy of adding cetuximab to taxane/platinum chemo-
therapy in patients with recurrent or metastatic NSCLC in a random-
ized controlled setting.
Methods: Patients with previously untreated stage IIIB (malignant 
pleural effusion) or stage IV NSCLC were eligible for this study. Pa-
tients on arm A received cetuximab (400 mg/m2 IV on day 1 followed 
by 250 mg/m2 weekly) combined with either paclitaxel (225 mg/m2 IV 
q3 weeks) or docetaxel (75mg mg/m2 IV q3 weeks) and carboplatin 
(AUC 6 IV q3 weeks). Patients on Arm B received the same chemo-
